Search

Your search keyword '"Arima, Nobuyoshi"' showing total 233 results
Start Over Author "Arima, Nobuyoshi"
233 results on '"Arima, Nobuyoshi"'

1. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

Author

Nakamura, Naokazu, Arima, Nobuyoshi, Takakuwa, Teruhito, Yoshioka, Satoshi, Imada, Kazunori, Fukushima, Kentaro, Hotta, Masaaki, Fuchida, Shin-ichi, Kanda, Junya, Uoshima, Nobuhiko, Shimura, Yuji, Tanaka, Hirokazu, Ohta, Kensuke, Kosugi, Satoru, Yagi, Hideo, Yoshihara, Satoshi, Yamamura, Ryosuke, Adachi, Yoko, Hanamoto, Hitoshi, Shibayama, Hirohiko, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, Kuroda, Junya, Matsumura, Itaru, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

4. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan

Author

Iemura, Tomoki, Kondo, Tadakazu, Ueda, Atsushi, Maeda, Takeshi, Kitawaki, Toshio, Arai, Yasuyuki, Kanda, Junya, Ikeda, Takashi, Imada, Kazunori, Ishikawa, Takayuki, Anzai, Naoyuki, Itoh, Mitsuru, Takeoka, Tomoharu, Akasaka, Takashi, Yago, Kazuhiro, Yonezawa, Akihito, Arima, Nobuyoshi, Kitano, Toshiyuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Moriguchi, Toshinori, Yamashita, Kouhei, Ueda, Yasunori, Matsumoto, Kana, and Takaori-Kondo, Akifumi

Published
2023
Full Text
View/download PDF

6. Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation

Author

Iemura, Tomoki, Arai, Yasuyuki, Kitawaki, Toshio, Kanda, Junya, Kondo, Tadakazu, Ueda, Yasunori, Mori, Takuto, Imada, Kazunori, Yonezawa, Akihito, Yago, Kazuhiro, Anzai, Naoyuki, Kotani, Shinichi, Nohgawa, Masaharu, Kitano, Toshiyuki, Itoh, Mitsuru, Arima, Nobuyoshi, Moriguchi, Toshinori, Watanabe, Mitsumasa, Tsuji, Masaaki, Yamashita, Kouhei, and Takaori-Kondo, Akifumi

Published
2022
Full Text
View/download PDF

7. Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning

Author

Iwasaki, Makoto, Kanda, Junya, Arai, Yasuyuki, Kondo, Tadakazu, Ishikawa, Takayuki, Ueda, Yasunori, Imada, Kazunori, Akasaka, Takashi, Yonezawa, Akihito, Yago, Kazuhiro, Nohgawa, Masaharu, Anzai, Naoyuki, Moriguchi, Toshinori, Kitano, Toshiyuki, Itoh, Mitsuru, Arima, Nobuyoshi, Takeoka, Tomoharu, Watanabe, Mitsumasa, Hirata, Hirokazu, Asagoe, Kosuke, Miyatsuka, Isao, An, Le My, Miyanishi, Masanori, and Takaori-Kondo, Akifumi

Published
2022
Full Text
View/download PDF

9. COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study.

Author

Nakamura, Naokazu, Tsunemine, Hiroko, Ikunari, Ryo, Sakai, Tomomi, and Arima, Nobuyoshi

Subjects
ANTIBODY titer, BLOOD diseases, MULTIPLE regression analysis, LONGITUDINAL method, PSOAS muscles
Abstract

Knowledge of the SARS-CoV-2 antibody titers induced by tixagevimab–cilgavimab in patients with hematologic diseases remains insufficient. Here, we performed a single-center, prospective study to reveal the changes in antibody titer after administration of tixagevimab–cilgavimab in 78 patients with hematologic diseases. The median peak titer was 155.4 U/mL, and the median AUC was 46556 days·U/mL. First, we compared several characteristics between patients with low titers (peak titer ≤ 155.4 U/mL) and high titers (peak titer > 155.4 U/mL). We extracted 6 factors (patient age, sex, ECOG-PS, serum albumin level, and cross-sectional area and computed tomographic number of the psoas major muscle) as candidates influencing the antibody titers. Multiple regression analysis revealed that antibody titer was closely associated with these 6 factors (contribution rate = 0.76, p = 0.02). Our data support the inability of tixagevimab–cilgavimab to induce sufficient antibody titers against SARS-CoV-2, especially in older, frailer, female patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group

Author

Watanabe, Mizuki, Kanda, Junya, Arai, Yasuyuki, Hishizawa, Masakatsu, Nishikori, Momoko, Ishikawa, Takayuki, Imada, Kazunori, Ueda, Yasunori, Akasaka, Takashi, Yonezawa, Akihito, Nohgawa, Masaharu, Kitano, Toshiyuki, Itoh, Mitsuru, Takeoka, Tomoharu, Moriguchi, Toshinori, Yago, Kazuhiro, Arima, Nobuyoshi, Anzai, Naoyuki, Watanabe, Mitsumasa, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Published
2020
Full Text
View/download PDF

11. Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-Matched Allogeneic Transplantation: A Japanese National Registry Study

Author

Arima, Nobuyoshi, Kanda, Junya, Yabe, Toshio, Morishima, Yasuo, Tanaka, Junji, Kako, Shinichi, Sakaguchi, Hirotoshi, Kato, Motohiro, Ohashi, Kazuteru, Ozawa, Yukiyasu, Fukuda, Takahiro, Ota, Shuichi, Tachibana, Takayoshi, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Yoshinobu

Published
2020
Full Text
View/download PDF

12. Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings

Author

Morishima, Yasuo, Morishima, Satoko, Murata, Makoto, Arima, Nobuyoshi, Uchida, Naoyuki, Sugio, Yasuhiro, Takahashi, Satoshi, Matsuhashi, Yoshiko, Onizuka, Makoto, Eto, Tetsuya, Nagafuji, Koji, Onishi, Yasushi, Inoue, Masami, Atsuta, Yoshiko, Fukuda, Takahiro, Ichinohe, Tatsuo, Kato, Shunichi, and Kanda, Junya

Published
2020
Full Text
View/download PDF

13. Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic Malignancy

Author

Morita-Fujita, Mari, Shindo, Takero, Iemura, Tomoki, Arai, Yasuyuki, Kanda, Junya, Okada, Kazuya, Ueda, Yasunori, Yoshiyuki, Onda, Anzai, Naoyuki, Mori, Takuto, Ishikawa, Takayuki, Otsuka, Yasuyuki, Yonezawa, Akihito, Yuhi, Naoki, Imada, Kazunori, Oba, Akifumi, Itoh, Mitsuru, Okamoto, Yoshio, Kitano, Toshiyuki, Ikeda, Takashi, Kotani, Shinichi, Akasaka, Takashi, Yago, Kazuhiro, Watanabe, Mitsumasa, Nohgawa, Masaharu, Tsuji, Masaaki, Takeoka, Tomoharu, Yamamoto, Ryusuke, Arima, Nobuyoshi, Yoshinaga, Noriyoshi, Hishizawa, Masakatsu, Yamashita, Kouhei, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Published
2023
Full Text
View/download PDF

17. Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry.

Author

Maeda, Tomoya, Matsuda, Akira, Kanda, Junya, Kawabata, Hiroshi, Ishikawa, Takayuki, Tohyama, Kaoru, Kitanaka, Akira, Araseki, Kayano, Shimbo, Kei, Hata, Tomoko, Suzuki, Takahiro, Kayano, Hidekazu, Usuki, Kensuke, Shindo‐Ueda, Maki, Arima, Nobuyoshi, Nohgawa, Masaharu, Ohta, Akiko, Chiba, Shigeru, Miyazaki, Yasushi, and Nakao, Shinji

Subjects
APLASTIC anemia, DYSPLASIA, AGE differences, OVERALL survival, ADULTS, PAROXYSMAL hemoglobinuria
Abstract

Summary: Morphological dysplasia in haematopoietic cells, defined by a 10% threshold in each lineage, is one of the diagnostic criteria for myelodysplastic neoplasms. Dysplasia limited to the erythroid lineage has also been reported in some cases of aplastic anaemia (AA); however, its significance remains unclear. We herein examined the impact of erythroid dysplasia on immunosuppressive therapy responses and survival in AA patients. The present study included 100 eligible AA patients without ring sideroblasts. Among them, 32 had dysplasia in the erythroid lineage (AA with minimal dysplasia [mini‐D]). No significant sex or age differences were observed between AA groups with and without erythroid dysplasia. In severe/very severe AA and non‐severe AA patients, a response to anti‐thymocyte globulin + ciclosporin within 12 months was observed in 80.0% and 60.0% of AA with mini‐D and 42.9% and 90.0% of those without dysplasia, with no significant difference (p = 0.29 and p = 0.24 respectively). Overall survival and leukaemia‐free survival did not significantly differ between the groups. Collectively, the present results indicate that the presence of erythroid dysplasia did not significantly affect clinical characteristics or outcomes in AA patients, suggesting that its presence in AA is acceptable. Therefore, erythroid dysplasia should not exclude an AA diagnosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study

Author

Matsuda, Akira, Kawabata, Hiroshi, Tohyama, Kaoru, Maeda, Tomoya, Araseki, Kayano, Hata, Tomoko, Suzuki, Takahiro, Kayano, Hidekazu, Shimbo, Kei, Usuki, Kensuke, Chiba, Shigeru, Ishikawa, Takayuki, Arima, Nobuyoshi, Nohgawa, Masaharu, Ohta, Akiko, Miyazaki, Yasushi, Nakao, Sinnji, Ozawa, Keiya, Arai, Shunya, Kurokawa, Mineo, Mitani, Kinuko, and Takaori-Kondo, Akifumi

Published
2018
Full Text
View/download PDF

19. Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia

Author

Arima, Nobuyoshi, Kanda, Junya, Tanaka, Junji, Yabe, Toshio, Morishima, Yasuo, Kim, Sung-Won, Najima, Yuho, Ozawa, Yukiyasu, Eto, Tetsuya, Kanamori, Heiwa, Mori, Takehiko, Kobayashi, Naoki, Kondo, Tadakazu, Nakamae, Hirohisa, Uchida, Naoyuki, Inoue, Masami, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Yoshinobu

Published
2018
Full Text
View/download PDF

20. Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes

Author

Kawabata, Hiroshi, Usuki, Kensuke, Shindo-Ueda, Maki, Kanda, Junya, Tohyama, Kaoru, Matsuda, Akira, Araseki, Kayano, Hata, Tomoko, Suzuki, Takahiro, Kayano, Hidekazu, Shimbo, Kei, Chiba, Shigeru, Ishikawa, Takayuki, Arima, Nobuyoshi, Nohgawa, Masaharu, Miyazaki, Yasushi, Kurokawa, Mineo, Arai, Shunya, Mitani, Kinuko, and Takaori-Kondo, Akifumi

Published
2019
Full Text
View/download PDF

22. Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study

Author

Arima, Nobuyoshi, Nakamura, Fumiaki, Yabe, Toshio, Tanaka, Junji, Fuji, Shigeo, Ohashi, Kazuteru, Fukuda, Takahiro, Miyamura, Koichi, Iwato, Koji, Eto, Tetsuya, Mori, Takehiko, Kobayashi, Naoki, Hoshino, Takumi, Kato, Chiaki, Kanamori, Heiwa, Nakamae, Hirohisa, Atsuta, Yoshiko, Morishima, Yasuo, and Kanda, Yoshinobu

Published
2016
Full Text
View/download PDF

23. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations

Author

Okabe, Masahiro, Yamaguchi, Hiroki, Usuki, Kensuke, Kobayashi, Yutaka, Kawata, Eri, Kuroda, Junya, Kimura, Shinya, Tajika, Kenji, Gomi, Seiji, Arima, Nobuyoshi, Mori, Sinichiro, Ito, Shigeki, Koizumi, Masayuki, Ito, Yoshikazu, Wakita, Satoshi, Arai, Kunihito, Kitano, Tomoaki, Kosaka, Fumiko, Dan, Kazuo, and Inokuchi, Koiti

Published
2016
Full Text
View/download PDF

24. Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies

Author

Wada, Fumiya, Kanda, Junya, Yoshioka, Satoshi, Ishikawa, Takayuki, Akasaka, Takashi, Ueda, Yasunori, Hirata, Hirokazu, Arai, Yasuyuki, Yago, Kazuhiro, Anzai, Naoyuki, Watanabe, Mitsumasa, Ikeda, Takashi, Yonezawa, Akihito, Imada, Kazunori, Itoh, Mitsuru, Kitano, Toshiyuki, Takeoka, Tomoharu, Hishizawa, Masakatsu, Nohgawa, Masaharu, Arima, Nobuyoshi, Asagoe, Kousuke, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Subjects
Transplantation, endocrine system, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, fluids and secretions, Recurrence, Hematologic Neoplasms, embryonic structures, Humans, Cord Blood Stem Cell Transplantation, Unrelated Donors, Cyclophosphamide, Retrospective Studies
Abstract

[Background.] Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) have become alternative options to treat patients with hematological malignancies without a HLA-matched donor. [Methods.] We conducted a retrospective study using registry data from the Kyoto Stem Cell Transplantation Group for patients with hematological malignancies who received their first allogeneic hematopoietic cell transplantation using a single UCB unit (n = 460) or PTCy-haplo (N = 57) between 2013 and 2019. [Results.] We found that overall survival in the UCB group was comparable to that in the PTCy-haplo group (hazard ratio, 1.00; 95% confidence interval, 0.66-1.52), although neutrophil and platelet engraftment were significantly delayed. Nonrelapse mortality risk and the incidence of graft-versus-host disease in the UCB group were also comparable to those in the PTCy-haplo group. Although the relapse risk was similar between the UCB group and the PTCy-haplo group regardless of the disease risk, acute myeloid leukemia patients benefit from UCB transplant with a significantly lower relapse rate (hazard ratio, 0.38; 95% confidence interval, 0.18-0.76). [Conclusions.] UCB transplant gives outcomes comparable to PTCy-haplo transplant, and both UCB and PTCy-haplo units are suitable as alternative donor sources for patients without an HLA-matched sibling or unrelated donor.

Published
2022

25. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation

Author

30636311, 10826564, Wada, Fumiya, Kanda, Junya, Kamijo, Kimimori, Nishikubo, Masashi, Yoshioka, Satoshi, Ishikawa, Takayuki, Ueda, Yasunori, Akasaka, Takashi, Arai, Yasuyuki, Izumi, Kiyotaka, Hirata, Hirokazu, Ikeda, Takashi, Yonezawa, Akihito, Anzai, Naoyuki, Watanabe, Mitsumasa, Imada, Kazunori, Yago, Kazuhiro, Tamura, Naoki, Itoh, Mitsuru, Masuo, Yuki, Kunitomi, Akane, Takeoka, Tomoharu, Kitano, Toshiyuki, Arima, Nobuyoshi, Hishizawa, Masakatsu, Asagoe, Kohsuke, Kondo, Tadakazu, Takaori-Kondo, Akifumi, 30636311, 10826564, Wada, Fumiya, Kanda, Junya, Kamijo, Kimimori, Nishikubo, Masashi, Yoshioka, Satoshi, Ishikawa, Takayuki, Ueda, Yasunori, Akasaka, Takashi, Arai, Yasuyuki, Izumi, Kiyotaka, Hirata, Hirokazu, Ikeda, Takashi, Yonezawa, Akihito, Anzai, Naoyuki, Watanabe, Mitsumasa, Imada, Kazunori, Yago, Kazuhiro, Tamura, Naoki, Itoh, Mitsuru, Masuo, Yuki, Kunitomi, Akane, Takeoka, Tomoharu, Kitano, Toshiyuki, Arima, Nobuyoshi, Hishizawa, Masakatsu, Asagoe, Kohsuke, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Abstract

Haploidentical-related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) and cord blood transplantation (CBT) are valid alternatives for patients with hematological malignancies when HLA-matched donor transplantation (MDT) is unavailable. However, the effects of graft-versus-host disease (GVHD) on outcomes after these transplants have not been fully elucidated. Therefore, we evaluated the effects of acute and chronic GVHD on transplant outcomes after PTCy-haplo transplants and compared them with CBT and MDT. We included a total of 914 adult patients with hematological malignancies in the Kyoto Stem Cell Transplantation Group registry who received PTCy-haplo (N = 120), CBT (N = 402), and MDT (N = 392), and achieved neutrophil engraftment. A multivariate analysis revealed that grade I-II acute GVHD improved of overall survival (OS) after PTCy-haplo [hazard ratio (HR) = 0.39, P = 0.018] and CBT (HR = 0.48, P < 0.001), but not after MDT (HR = 0.80, P = 0.267) compared with patients without acute GVHD. Grade I-II acute GVHD had a trend toward reducing the risk of nonrelapse mortality (NRM) after PTCy-haplo (HR = 0.13, P = 0.060) and this positive effect was significant after CBT (HR = 0.39, P = 0.003). A negative impact of grade III-IV acute GVHD on NRM was observed after CBT and MDT, but not after PTCy-haplo. Limited chronic GVHD had a positive impact on OS after CBT and MDT, but not after PTCy-haplo. In conclusion, mild acute GVHD improved outcomes after PTCy-haplo and CBT, and limited chronic GVHD improved outcomes after CBT and MDT. These data indicated that the effects of GVHD on transplant outcomes depended on transplant platforms.

Published
2023

26. Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry

Author

Kawabata, Hiroshi, Tohyama, Kaoru, Matsuda, Akira, Araseki, Kayano, Hata, Tomoko, Suzuki, Takahiro, Kayano, Hidekazu, Shimbo, Kei, Zaike, Yuji, Usuki, Kensuke, Chiba, Shigeru, Ishikawa, Takayuki, Arima, Nobuyoshi, Nogawa, Masaharu, Ohta, Akiko, Miyazaki, Yasushi, Mitani, Kinuko, Ozawa, Keiya, Arai, Shunya, Kurokawa, Mineo, Takaori-Kondo, Akifumi, and The Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes

Published
2017
Full Text
View/download PDF

29. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation

Author

Wada, Fumiya, primary, Kanda, Junya, additional, Kamijo, Kimimori, additional, Nishikubo, Masashi, additional, Yoshioka, Satoshi, additional, Ishikawa, Takayuki, additional, Ueda, Yasunori, additional, Akasaka, Takashi, additional, Arai, Yasuyuki, additional, Izumi, Kiyotaka, additional, Hirata, Hirokazu, additional, Ikeda, Takashi, additional, Yonezawa, Akihito, additional, Anzai, Naoyuki, additional, Watanabe, Mitsumasa, additional, Imada, Kazunori, additional, Yago, Kazuhiro, additional, Tamura, Naoki, additional, Itoh, Mitsuru, additional, Masuo, Yuki, additional, Kunitomi, Akane, additional, Takeoka, Tomoharu, additional, Kitano, Toshiyuki, additional, Arima, Nobuyoshi, additional, Hishizawa, Masakatsu, additional, Asagoe, Kohsuke, additional, Kondo, Tadakazu, additional, and Takaori-Kondo, Akifumi, additional

Published
2023
Full Text
View/download PDF

32. Effects of combined test-dose and therapeutic drug monitoring strategy in exposure-directed busulfan

Author

Iemura, Tomoki, primary, Kondo, Tadakazu, additional, Ueda, Atsushi, additional, Maeda, Takeshi, additional, Kitawaki, Toshio, additional, Arai, Yasuyuki, additional, Kanda, Junya, additional, Ikeda, Takashi, additional, Imada, Kazunori, additional, Ishikawa, Takayuki, additional, Anzai, Naoyuki, additional, Itoh, Mitsuru, additional, Takeoka, Tomoharu, additional, Akasaka, Takashi, additional, Yago, Kazuhiro, additional, Yonezawa, Akihito, additional, Arima, Nobuyoshi, additional, Kitano, Toshiyuki, additional, Nohgawa, Masaharu, additional, Watanabe, Mitsumasa, additional, Moriguchi, Toshinori, additional, Yamashita, Kouhei, additional, Ueda, Yasunori, additional, Matsumoto, Kana, additional, and Takaori-Kondo, Akifumi, additional

Published
2022
Full Text
View/download PDF

33. Resistance of KIR ligand-missing leukocytes to natural killer cells in vivo in patients with acquired aplastic anemia

Author

Nguyen Thi, Mai Anh, Hosokawa, Kohei, Yoroidaka, Takeshi, Maruyama, Hiroyuki, Espinoza, J. Luis, Elbadry, Mahmoud I., Md, Mohiuddin, Tanabe, Mikoto, Katagiri, Takamasa, Nakagawa, Noriharu, Arima, Nobuyoshi, Kashiwase, Koichi, Saji, Hiroh, Ogawa, Seishi, and Nakao, Shinji

Subjects
aplastic anemia, Resistance of KIR-L(-) cells to NK cells in AA, killer cell immunoglobulin-like receptor, pLOH
Abstract

金沢大学医薬保健研究域医学系 Graduate School of Medical Sciences, The loss of killer cell immunoglobulin-like receptor-ligands (KIR-Ls) due to the copy number neutral loss of heterozygosity of chromosome 6p (6pLOH) in leukocytes of patients with acquired aplastic anemia (AA) may alter the susceptibility of the affected leukocytes to NK cell killing in vivo. We studied 408 AA patients, including 261 who were heterozygous for KIR-Ls, namely C1/C2 or Bw6/Bw4, for the presence of KIR-L-missing (KIR-L[-]) leukocytes. KIR-L(-) leukocytes were found in 14 (5.4%, C1, n= 4, C2, n=3, and Bw4, n= 7) of the 261 patients, in whom corresponding KIR(+) licensed NK cells were detected. The incidence of 6pLOH in the 261 patients (18.0%) was comparable to that in 147 patients (13.6%) who were homozygous for KIR-L genes. The percentages of HLA-lacking granulocytes (0.8-50.3%, median 15.2%) in the total granulocytes of the patients with KIR-L(-) cells were significantly lower than those (1.2-99.4%, median 55.4%) in patients without KIR-L(-) cells. KIR2DS1 and KIR3DS1 were only possessed by three of the 14 patients, two of whom had C2/C2 leukocytes after losing C1 alleles. The expression of the KIR3DS1 ligand HLA-F was selectively lost on KIR-L(-) primitive hematopoietic stem cells (HSCs) derived from 6pLOH(+) iPS cells in one of the KIR3DS1(+) patients. These findings suggest that human NK cells are able to suppress the expansion of KIR-L(-) leukocytes but are unable to eliminate them partly due to the lack of activating KIRs on NK cells and the low HLA-F expression level on HSCs in AA patients., Embargo Period 6 months

Published
2020

34. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial

Author

30636311, 70217933, Muranushi, Hiroyuki, Kanda, Junya, Kobayashi, Masayuki, Maeda, Takeshi, Kitano, Toshiyuki, Tsuji, Masaaki, Ueda, Yasunori, Ishikawa, Takayuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Imada, Kazunori, Moriguchi, Toshinori, Itoh, Mitsuru, Ohno, Hitoshi, Yonezawa, Akihito, Hirata, Hirokazu, Arima, Nobuyoshi, Asagoe, Kohsuke, Anzai, Naoyuki, Nagata, Kayoko, Yasuno, Shinji, Kuwabara, Yoshihiro, Kitao, Hiromi, Kim, Ihhwa, Kawagishi, Kiyomi, Ueshima, Kenji, Tominari, Shinjiro, Nakayama, Takeo, Yamashita, Kouhei, Takaori-Kondo, Akifumi, 30636311, 70217933, Muranushi, Hiroyuki, Kanda, Junya, Kobayashi, Masayuki, Maeda, Takeshi, Kitano, Toshiyuki, Tsuji, Masaaki, Ueda, Yasunori, Ishikawa, Takayuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Imada, Kazunori, Moriguchi, Toshinori, Itoh, Mitsuru, Ohno, Hitoshi, Yonezawa, Akihito, Hirata, Hirokazu, Arima, Nobuyoshi, Asagoe, Kohsuke, Anzai, Naoyuki, Nagata, Kayoko, Yasuno, Shinji, Kuwabara, Yoshihiro, Kitao, Hiromi, Kim, Ihhwa, Kawagishi, Kiyomi, Ueshima, Kenji, Tominari, Shinjiro, Nakayama, Takeo, Yamashita, Kouhei, and Takaori-Kondo, Akifumi

Abstract

[Objectives:] We conducted a phase II trial to prospectively evaluate the efficacy and safety of bortezomib-cyclophosphamide-dexamethasone (VCD) induction, autologous stem cell transplantation (ASCT), VCD consolidation, and bortezomib maintenance in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients in Japan (UMIN000010542). [Methods:] From 2013 to 2016, 42 patients with a median age of 58 (range 42–65) years with NDMM were enrolled in 15 centers. The primary endpoint was the complete response (CR) /stringent CR (sCR) rate after transplantation, and overall/progression-free survival rates were also evaluated. [Results:] Following induction therapy, the overall response rate was obtained in 71% of patients, including a CR/sCR of 10% and a very good partial response (VGPR) of 26%. Twenty-six of the 42 patients completed ASCT following the protocol and CR/sCR and VGPR rate 100 days after ASCT was 26% and 17%, respectively. During consolidation therapy, 3 of the 24 patients achieved deeper responses. Eight of the 18 patients completed 2-year bortezomib maintenance without disease progression and grade 3/4 toxicities. Five patients were VGPR or partial response after ASCT but maintained response with 2-year bortezomib maintenance. Two-year overall and progression-free survival rates were 92.5% (95% confidence interval [CI]: 78.5%−97.5%) and 62.6% (95% CI: 45.8%−75.5%), respectively. Grade 3/4 toxicities (≥ 10%) included neutropenia (19%) and anemia (17%) in induction, and thrombocytopenia (29%) in consolidation. [Conclusion:] VCD induction/consolidation and bortezomib maintenance with ASCT for NDMM resulted in a high CR/sCR rate and provided good overall/progression-free survival in Japan.

Published
2022

35. Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies

Author

10826564, Wada, Fumiya, Kanda, Junya, Yoshioka, Satoshi, Ishikawa, Takayuki, Akasaka, Takashi, Ueda, Yasunori, Hirata, Hirokazu, Arai, Yasuyuki, Yago, Kazuhiro, Anzai, Naoyuki, Watanabe, Mitsumasa, Ikeda, Takashi, Yonezawa, Akihito, Imada, Kazunori, Itoh, Mitsuru, Kitano, Toshiyuki, Takeoka, Tomoharu, Hishizawa, Masakatsu, Nohgawa, Masaharu, Arima, Nobuyoshi, Asagoe, Kousuke, Kondo, Tadakazu, Takaori-Kondo, Akifumi, 10826564, Wada, Fumiya, Kanda, Junya, Yoshioka, Satoshi, Ishikawa, Takayuki, Akasaka, Takashi, Ueda, Yasunori, Hirata, Hirokazu, Arai, Yasuyuki, Yago, Kazuhiro, Anzai, Naoyuki, Watanabe, Mitsumasa, Ikeda, Takashi, Yonezawa, Akihito, Imada, Kazunori, Itoh, Mitsuru, Kitano, Toshiyuki, Takeoka, Tomoharu, Hishizawa, Masakatsu, Nohgawa, Masaharu, Arima, Nobuyoshi, Asagoe, Kousuke, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Abstract

[Background.] Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) have become alternative options to treat patients with hematological malignancies without a HLA-matched donor. [Methods.] We conducted a retrospective study using registry data from the Kyoto Stem Cell Transplantation Group for patients with hematological malignancies who received their first allogeneic hematopoietic cell transplantation using a single UCB unit (n = 460) or PTCy-haplo (N = 57) between 2013 and 2019. [Results.] We found that overall survival in the UCB group was comparable to that in the PTCy-haplo group (hazard ratio, 1.00; 95% confidence interval, 0.66-1.52), although neutrophil and platelet engraftment were significantly delayed. Nonrelapse mortality risk and the incidence of graft-versus-host disease in the UCB group were also comparable to those in the PTCy-haplo group. Although the relapse risk was similar between the UCB group and the PTCy-haplo group regardless of the disease risk, acute myeloid leukemia patients benefit from UCB transplant with a significantly lower relapse rate (hazard ratio, 0.38; 95% confidence interval, 0.18-0.76). [Conclusions.] UCB transplant gives outcomes comparable to PTCy-haplo transplant, and both UCB and PTCy-haplo units are suitable as alternative donor sources for patients without an HLA-matched sibling or unrelated donor.

Published
2022

36. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial

Author

Muranushi, Hiroyuki, primary, Kanda, Junya, additional, Kobayashi, Masayuki, additional, Maeda, Takeshi, additional, Kitano, Toshiyuki, additional, Tsuji, Masaaki, additional, Ueda, Yasunori, additional, Ishikawa, Takayuki, additional, Nohgawa, Masaharu, additional, Watanabe, Mitsumasa, additional, Imada, Kazunori, additional, Moriguchi, Toshinori, additional, Itoh, Mitsuru, additional, Ohno, Hitoshi, additional, Yonezawa, Akihito, additional, Hirata, Hirokazu, additional, Arima, Nobuyoshi, additional, Asagoe, Kohsuke, additional, Anzai, Naoyuki, additional, Nagata, Kayoko, additional, Yasuno, Shinji, additional, Kuwabara, Yoshihiro, additional, Kitao, Hiromi, additional, Kim, Ihhwa, additional, Kawagishi, Kiyomi, additional, Ueshima, Kenji, additional, Tominari, Shinjiro, additional, Nakayama, Takeo, additional, Yamashita, Kouhei, additional, and Takaori-Kondo, Akifumi, additional

Published
2022
Full Text
View/download PDF

39. Feasibility of the Routine Clinical Use of a Multiplex Virus Polymerase Chain Reaction Assay Based on Blood Virus Detection in Hematopoietic Stem Cell-Transplanted Patients

Author

Tsunemine, Hiroko, primary, Sasaki, Miho, additional, Zushi, Yuriko, additional, Saitoh, Toshiharu, additional, Shimizu, Norio, additional, Tomaru, Yasuhiro, additional, Aoyama, Yumi, additional, Yamamoto, Ryusuke, additional, Sakai, Tomomi, additional, Arima, Nobuyoshi, additional, Kodaka, Taiichi, additional, and Takahashi, Takayuki, additional

Published
2022
Full Text
View/download PDF

40. HLA-B Leader Dimorphism Impacts on Outcomes of HLA-Matched Related/Unrelated Transplantation: Analysis of the Japanese Society for Transplantation and Cellular Therapy

Author

Kanaya, Minoru, primary, Morishima, Yasuo, additional, Arima, Nobuyoshi, additional, Hirayama, Masahiro, additional, Shiratori, Souichi, additional, Doki, Noriko, additional, Ozawa, Yukiyasu, additional, Fukuda, Takahiro, additional, Tanaka, Masatsugu, additional, Sawa, Masashi, additional, Takada, Satoru, additional, Ota, Shuichi, additional, Kawakita, Toshiro, additional, Kanda, Junya, additional, Ichinohe, Tatsuo, additional, Atsuta, Yoshiko, additional, and Morishima, Satoko, additional

Published
2021
Full Text
View/download PDF

41. Single Cord Blood Transplantation Versus HLA-Haploidentical Related Donor Transplantation Using Post-Transplant Cyclophosphamide in Patients with Hematological Malignancies

Author

Wada, Fumiya, primary, Kanda, Junya, additional, Yoshioka, Satoshi, additional, Ishikawa, Takayuki, additional, Akasaka, Takashi, additional, Ueda, Yasunori, additional, Hirata, Hirokazu, additional, Arai, Yasuyuki, additional, Yago, Kazuhiro, additional, Anzai, Naoyuki, additional, Watanabe, Mitsumasa, additional, Ikeda, Takashi, additional, Yonezawa, Akihito, additional, Imada, Kazunori, additional, Itoh, Mitsuru, additional, Kitano, Toshiyuki, additional, Takeoka, Tomoharu, additional, Hishizawa, Masakatsu, additional, Nohgawa, Masaharu, additional, Arima, Nobuyoshi, additional, Asagoe, Kosuke, additional, Kondo, Tadakazu, additional, and Takaori-Kondo, Akifumi, additional

Published
2021
Full Text
View/download PDF

44. The HLA-B Leader MM Genotype Has a Negative Impact on Outcomes in HLA-B One Antigen Mismatched and HLA-B Matched Cord Blood Transplantation without Anti-Thymocyte Globulin: Analysis of the Japanese Society for Transplantation and Cellular Therapy

Author

Kanaya, Minoru, Hashimoto, Daigo, Morishima, Yasuo, Arima, Nobuyoshi, Hirayama, Masahiro, Murata, Makoto, Uchida, Naoyuki, Tanaka, Masatsugu, Uehara, Yasufumi, Miyakoshi, Shigesaburo, Ishiwata, Kazuya, Onizuka, Makoto, Takahashi, Satoshi, Kobayashi, Hikaru, Sawa, Masashi, Kato, Koji, Ishimaru, Fumihiko, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Morishima, Satoko

Published
2023
Full Text
View/download PDF

49. Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: A multicenter, retrospective analysis in Japan

Author

Takata, Katsuyoshi, Okada, Hiroyuki, Ohmiya, Naoki, Nakamura, Shotaro, Kitadai, Yasuhiko, Tari, Akira, Akamatsu, Taiji, Kawai, Hiroki, Tanaka, Shu, Araki, Hiroshi, Yoshida, Takashi, Okumura, Hirokazu, Nishisaki, Hogara, Sagawa, Tamotsu, Watanabe, Norihiko, Arima, Nobuyoshi, Takatsu, Noritaka, Nakamura, Masanao, Yanai, Shunichi, Kaya, Hiroyasu, Morito, Toshiaki, Sato, Yasuharu, Moriwaki, Hisataka, Sakamoto, Choitsu, Niwa, Yasumasa, Goto, Hidemi, Chiba, Tsutomu, Matsumoto, Takayuki, Ennishi, Daisuke, Kinoshita, Tomohiro, and Yoshino, Tadashi

Published
2011
Full Text
View/download PDF

50. THE ISSUES IN EARLY DETECTION OF ADVERSE REACTIONS BY NURSES BASED ON A TRANSFUSION-RELATED PATIENT OBSERVATION SURVEY

Author

Matsumoto, Mayumi, primary, Arima, Nobuyoshi, additional, Matsuura, Hideaki, additional, Nishioka, Junko, additional, Taniguchi, Yo, additional, Yamazaki, Yoshiko, additional, Murata, Mayumi, additional, Yamano, Yasuko, additional, Hosono, Akira, additional, Okuda, Makoto, additional, Abe, Makoto, additional, Kohno, Takehiro, additional, Kino, Shuichi, additional, Omokawa, Susumu, additional, Takeshita, Akihiro, additional, Muroi, Kazuo, additional, and Makino, Shigeyoshi, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results